Immunology startup TRex Bio sets price range for $133 million public debut
TRex Bio Inc., a biotech firm developing autoimmune treatments, aims to raise $133.3M in an IPO, offering 8.33M shares at $14-$16 each. The company's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027. Backed by investors like Eli Lilly and Pfizer Ventures, TRex Bio plans to use proceeds for clinical development and operations. It will list on Nasdaq under 'TRXB'.
How this was made
The 30-second read
Why it matters
The IPO will fund Phase 1b and Phase 1 trials, expanding its pipeline and potentially increasing valuation if data are positive.
Market read
First public disclosure of TRex Bio's IPO pricing range, offering a new tradeable biotech stock.
What to watch
Potential dilution for existing shareholders and reliance on early‑stage trial data.
Background
TRex Bio is a clinical‑stage company developing Treg‑based immunology therapies, backed by major pharma venture arms.
Market effects
Adds another biotech offering, may boost sector sentiment and peer valuations.
Supports US biotech financing activity on Nasdaq.
Limited to US biotech investors; no broader macro effect.
Counterpoint
If demand is weak, pricing may fall to the lower end, causing a post‑IPO dip.
Key entities
- investorEli Lilly & Co.
Existing shareholder planning to increase its stake up to 19.9%.
- underwriterJ.P. Morgan
Joint bookrunner for the offering.
